#USA #New York #Class Action #Pomerantz LLP #Replimune

Investor Alert: Class Action Lawsuit Against Replimune Group, Inc.

Pomerantz LLP recently announced that a class action lawsuit has been initiated against Replimune Group, Inc. (NASDAQ: REPL). This legal action targets investors who may have suffered financial losses while holding Replimune securities. Investors are urged to contact Danielle Peyton at Pomerantz for further details on how to participate in the class action.

The lawsuit arises from allegations that the company, alongside certain officers and directors, may have engaged in securities fraud along with other unlawful business practices. Investors who acquired Replimune securities within the specified class period have until October 5, 2026, to request the court appoint them as Lead Plaintiff in this case.

Background on Replimune's Regulatory Challenges

The legal issues facing Replimune stem from significant setbacks regarding its product development. On April 10, 2026, the U.S. Food and Drug Administration (FDA) released a Complete Response Letter (CRL) concerning Replimune's Biologics License Application (BLA) for the treatment RP1 in combination with nivolumab. The FDA identified multiple deficiencies in the studies submitted by the company, indicating that the data provided did not meet the necessary standards for regulatory approval.

The FDA concluded that the trial results were inadequate, stating that additional exploratory analyses offered by Replimune did not change their assessment. Furthermore, there were concerns raised about the study's design, which had previously been communicated to Replimune multiple times throughout the drug's development process.

Following the announcement of the FDA's preliminary feedback, Replimune's stock experienced a significant downturn, closing at $4.76 per share—a drop of 19.46%. Subsequently, after clarifying the FDA's concerns in a press release, the company's share price plunged again by 64.29%, hitting a low of $1.70 per share by April 13, 2026. Such stark declines in the stock price highlight the potential financial losses faced by investors, fueling the class action litigation.

Pomerantz LLP's Role in the Case

Pomerantz LLP is celebrated for its expertise in corporate, securities, and antitrust class litigation, having pioneered the field of securities class actions over 85 years ago. Founded by Abraham L. Pomerantz, a notable figure in securities law, the firm has a rich history of advocating for victims of securities fraud and corporate misconduct. Pomerantz has successfully recovered substantial settlements and damages for investors in the past.

For those impacted by the recent developments with Replimune, participating in the class action may present a pathway to seek reparative measures. Interested parties can contact Pomerantz LLP through their dedicated channels to obtain more information about this ongoing legal process.

Conclusion

As the situation continues to unfold, it remains crucial for investors affected by Replimune's recent challenges to stay informed and consider their rights. The firm urges any investor who has suffered losses to consider joining the class action and to contact their office for assistance. Investor rights are at the forefront of Pomerantz LLP's mission, and they aim to ensure that those affected by potential securities fraud have their voices heard.

For more information, potential class members can reach out to Pomerantz LLP at

• - Email: [email protected]
• - Phone: 646-581-9980, ext. 7980

The legal landscape surrounding Replimune is developing, and interested investors are encouraged to act swiftly to protect their interests.